Highly Sensitive Single LC-MS/MS Method for Cleaning Validation of Synthetic Peptides Using Shimadzu LCMS-8060

Importance of the Topic

Cleaning validation in pharmaceutical manufacturing is crucial to avoid cross contamination and ensure patient safety. Synthetic peptides present additional challenges due to poor ionization, non-specific adsorption and carry-over, requiring highly sensitive analytical methods.

Objectives and Study Overview

This study aimed to develop a single, rapid LC-MS/MS method using Shimadzu LCMS-8060 for quantifying six synthetic peptides (abaloparatide, cosyntropin, ganirelix, glucagon, liraglutide, semaglutide) at a lower limit of quantification (LLOQ) of 0.5 ng/mL to support cleaning validation.

Methodology and Used Instrumentation

Sample Preparation:

• Primary stock: 1 mg/mL peptides in DMSO:methanol (10:90, v/v).
• Intermediate stock: 1 µg/mL in methanol:water (50:50, v/v).
• Calibration standards: 0.5–250 ng/mL (abaloparatide, cosyntropin) and 0.5–500 ng/mL (other peptides) in acetonitrile:water (50:50, v/v) with 1% formic acid.

Chromatography and Mass Spectrometry:

• UHPLC: Nexera X2 with Shim-pack Velox C18 column (100×2.1 mm, 2.7 µm) at 60 °C.
• Mobile phase A: 1% formic acid in water; B: 1% formic acid in acetonitrile; gradient from 0% to 100% B over 10 min, flow rate 0.20 mL/min, re-equilibration 1.5 min.
• Mass spectrometer: LCMS-8060 with heated ESI and UF-Qarray™ ion guide, ESI positive mode (interface temperature 300 °C, voltage 4 kV), MRM detection.

Main Results and Discussion

The method achieved an LLOQ of 0.5 ng/mL for all six peptides with linearity (r2>0.98) across defined calibration ranges. Optimized MRM transitions and collision energies provided specific detection: Q1 precursor m/z and dominant charge states ranged from +3 to +6, yielding characteristic product ions. The method addressed non-specific binding and low sensitivity, delivering well-shaped peaks and minimal background noise within a 10 min run time.

Benefits and Practical Applications

The developed assay supports cleaning validation by reliably quantifying multiple therapeutic peptides in a single analysis. Its high sensitivity and robustness make it suitable for regulated environments, reducing method development time and ensuring compliance with GMP guidelines.

Future Trends and Potential Applications

Advancements may include expanding the method to additional peptide classes, integrating automation for high-throughput cleaning validation, and adapting workflows for biological sample analysis in pharmacokinetic and toxicology studies.

Conclusion

A single LC-MS/MS method on Shimadzu LCMS-8060 was successfully developed for simultaneous quantification of six synthetic peptides with high sensitivity (LLOQ 0.5 ng/mL), linearity, and selectivity. This approach streamlines cleaning validation and enhances quality assurance in peptide manufacturing.

References

1. World Health Organization (2011) Supplementary guidelines on good manufacturing practices for the manufacture of sterile pharmaceutical products. WHO Technical Report Series No. 937, Annex 4.